全文获取类型
收费全文 | 19006篇 |
免费 | 1155篇 |
国内免费 | 1691篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 217篇 |
妇产科学 | 186篇 |
基础医学 | 2495篇 |
口腔科学 | 41篇 |
临床医学 | 1568篇 |
内科学 | 7899篇 |
皮肤病学 | 38篇 |
神经病学 | 48篇 |
特种医学 | 148篇 |
外科学 | 725篇 |
综合类 | 2772篇 |
预防医学 | 3691篇 |
眼科学 | 8篇 |
药学 | 1312篇 |
11篇 | |
中国医学 | 284篇 |
肿瘤学 | 401篇 |
出版年
2023年 | 130篇 |
2022年 | 354篇 |
2021年 | 508篇 |
2020年 | 462篇 |
2019年 | 471篇 |
2018年 | 472篇 |
2017年 | 406篇 |
2016年 | 642篇 |
2015年 | 821篇 |
2014年 | 1348篇 |
2013年 | 1272篇 |
2012年 | 1368篇 |
2011年 | 1588篇 |
2010年 | 1297篇 |
2009年 | 1264篇 |
2008年 | 1093篇 |
2007年 | 1280篇 |
2006年 | 1114篇 |
2005年 | 1022篇 |
2004年 | 701篇 |
2003年 | 605篇 |
2002年 | 558篇 |
2001年 | 490篇 |
2000年 | 418篇 |
1999年 | 407篇 |
1998年 | 309篇 |
1997年 | 285篇 |
1996年 | 164篇 |
1995年 | 213篇 |
1994年 | 197篇 |
1993年 | 90篇 |
1992年 | 89篇 |
1991年 | 50篇 |
1990年 | 59篇 |
1989年 | 51篇 |
1988年 | 48篇 |
1987年 | 40篇 |
1986年 | 37篇 |
1985年 | 28篇 |
1984年 | 15篇 |
1983年 | 10篇 |
1982年 | 7篇 |
1981年 | 10篇 |
1980年 | 7篇 |
1979年 | 9篇 |
1978年 | 8篇 |
1977年 | 6篇 |
1976年 | 5篇 |
1974年 | 5篇 |
1972年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 301 毫秒
21.
Amedeo Lonardo Alessandro Mantovani 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(8):2354-2357
Liver health is a key determinant of cardiovascular risk (CVR). Hepatic fibrosis is the shared common result of chronic hepatitis, irrespective of aetiology. Fibrosis profoundly distorts liver tissue architecture and perturbs hepatic physiology, dictates the course of chronic liver disease and is increasingly recognized as a CVR factor. The relative weights of pre-diabetes and hepatic fibrosis as risk factors for major adverse cardiac events (MACE) in patients with HCV remain an open issue. Sasso and Colleagues answered this research question by treating approximately half of 770 HCV positive pre-diabetic patients with direct antiviral agents (DAAs), while the rest served as historical controls. Data have shown that achieving HCV clearance with DAAs was associated with a 60% reduced risk of MACE, thereby implying that this antiviral strategy is recommended in HCV positive pre-diabetic patients, regardless of the severity of liver disease and concurrent CVR factors. This study paves the way for additional studies addressing the molecular patho-mechanisms and changes in the clinical spectrum involved in cardio-metabolic protection following HCV eradication in patients with pre-diabetes. 相似文献
22.
23.
24.
25.
Hepatitis C is a major public health problem worldwide. This disease is caused by the hepatitis C virus, which is characterised by its genetic diversity. The infection is usually asymptomatic. However, between 60% and 80% of HCV-infected individuals will progress to chronic hepatitis, 20% to liver cirrhosis in the medium-to long-term and, each year, between 1% and 4% of these patients with cirrhosis will develop hepatocellular carcinoma (HCC). A Spanish consensus document has recently been drafted to diagnose hepatitis C in a single step, consisting of active investigation (antibodies and viremia) in a single sample, which according to the experts, would reduce the time to access treatment and avoid tracking losses. To definitively change the hepatitis C treatment paradigm, direct-acting antiviral drugs (DAAs) have been approved, whose development has been based on achieving cure rates close to 100% regardless of the genotype of the virus, ie, pangenotypes, with good tolerance and bioavailability. These drugs have constituted a real therapeutic revolution. Supplement information: This article is part of a supplement entitled «SEIMC External Quality Control Programme. Year 2016», which is sponsored by Roche, Vircell Microbiologists, Abbott Molecular and Francisco Soria Melguizo, S.A.© 2019 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosasy Microbiología Clínica. All rights reserved. 相似文献
26.
27.
28.
29.
李超明 《实用医学影像杂志》2021,(1)
目的评价恩替卡韦治疗慢性乙型肝炎肝纤维化的疗效,并使用肝脏实时剪切波弹性成像和超声量化评分对疗效进行对比分析。方法选择在2017年10月至2018年3月本院收治的54例慢性乙型肝炎肝纤维化患者,对其进行肝脏实时剪切波弹性成像和超声量化检查,之后对患者实施恩替卡韦治疗,治疗周期为1年,治疗后再次实施肝脏实时剪切波弹性成像和超声量检查,对2次检查的各项指标进行对比,分析检查指标的差异。结果治疗前S1-S3期与S4期超声评分、肝硬度进行对比,差异有统计学意义,治疗后患者超声评分、肝硬度(kPa)指标低于治疗前(P<0.05)。结论恩替卡韦治疗慢性乙型肝炎肝纤维化疗效较为显著,同时在进行病情评估的过程中实施肝脏实时剪切波弹性成像和超声量化评分,可以对肝脏疾病的不同阶段进行分期,检查和治疗的效果均较为理想。 相似文献
30.
Ferdinando Carlo Sasso Pia Clara Pafundi Alfredo Caturano Raffaele Galiero Erica Vetrano Riccardo Nevola Salvatore Petta Anna Ludovica Fracanzani Carmine Coppola Vito Di Marco Antonio Solano Rosa Lombardi Mauro Giordano Antonio Craxi Alessandro Perrella Celestino Sardu Raffaele Marfella Teresa Salvatore Luca Rinaldi 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(8):2345-2353
Background and aimsBeyond type 2 diabetes, even a condition of prediabetes is associated with an increased cardiovascular (CV) risk, and HCV infection coexistence represents an exacerbating factor. CV prognosis improvement in prediabetes represents a challenge, due to the increasing prevalence of this metabolic condition worldwide. Hence, we aimed to prospectively assess how direct acting antivirals (DAAs) could affect major cardiovascular events (MACE) in a prediabetic HCV positive cohort.Methods and resultsIn this prospective multicenter study, we enrolled HCV patients with overt prediabetes. We compared a subgroup of patients treated with DAAs with untreated prediabetic controls. We recorded all CV events occurred during an overall median follow-up of 24 months (IQR 19–34). 770 HCV positive prediabetic patients were enrolled, 398 untreated controls and 372 DAAs treated patients. Overall, the CV events annual incidence was much higher among prediabetic treated patients (1.77 vs. 0.62, p < 0.001), and HCV clearance demonstrated to significantly reduce CV events (RR: 0.411, 95%CI 0.148–1.143; p < 0.001), with an estimated NNT for one additional patient to benefit of 52.1. Moreover, an independent association between a lower rate of CV events and HCV clearance after DAAs was observed (OR 4.67; 95%CI 0.44–53.95; p = 0.016).ConclusionsHCV eradication by DAAs allows a significant reduction of MACEs in the prediabetic population, and therefore represents a primary objective, regardless of the severity of liver disease and CV risk factors. 相似文献